Previous 10 | Next 10 |
Introduction It’s closing in on almost 3-years since I first published my initial write-up on Viking Therapeutics ( VKTX ) back in Oct-2017. I’ve had plenty to say about the company since that time, publishing numerous other articles along the way, but more recently I’...
Intercept Pharmaceuticals (NASDAQ: ICPT) isn't exactly having a summer to remember, but the second-quarter results it delivered early Monday were quite encouraging. For the period, the company's total revenue came in at $77.2 million, up 16% year over year. Its net loss narrowed over that s...
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q2 2020 Earnings Call Aug 10, 2020 , 8:30 a.m. ET Operator Continue reading
Intercept Pharmaceuticals, Inc. (ICPT) Q2 2020 Earnings Call August 10, 2020 8:30 am ET Executives Lisa M. DeFrancesco - Intercept Pharmaceuticals, Inc. Mark E. Pruzanski - Intercept Pharmaceuticals, Inc. Jerome B. Durso - Intercept Pharmaceuticals, Inc. Sandip S. Kapadia - Int...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Intercept Pharma ( ICPT ) Q2 results : More news on: Intercept Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Stocks on the move, Read more ...
Intercept Pharma (NASDAQ: ICPT ) : Q2 GAAP EPS of -$1.92 beats by $1.01 . More news on: Intercept Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Worldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarter Intercept issues 2020 Ocaliva Net Sales Guidance of $300 to $320 million Intercept lowers 2020 non-GAAP Adjusted Operating Expense Guidance by $100 mil...
Intercept Pharma (NASDAQ: ICPT ) is scheduled to announce Q2 earnings results on Monday, August 10th, before market open. The consensus EPS Estimate is -$2.81 (-23.2% Y/Y) and the consensus Revenue Estimate is $72.45M (+9.3% Y/Y). Analyst expects net Ocaliva sales estimate of $71M. O...
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2020 financial result...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...